Recombinant Anti-cdr-bi-single-chain-fv-diphtheria Toxin Fusion Protein
Recombinant Anti-cdr-bi-single-chain-fv-diphtheria Toxin Fusion Protein Uses, Dosage, Side Effects, Food Interaction and all others data.
Recombinant Anti-cdr-bi-single-chain-fv-diphtheria Toxin Fusion Protein is under investigation in clinical trial NCT02943642 (Safety and Effectiveness of A-dmdt390-bisfv(ucht1) Fusion Protein in Subjects With Mycosis Fungoides).
| Trade Name | Recombinant Anti-cdr-bi-single-chain-fv-diphtheria Toxin Fusion Protein |
| Generic | A-dmDT390-bisFv(UCHT1) |
| A-dmDT390-bisFv(UCHT1) Other Names | Anti-cd3 immunotoxin a-dmdt390-bisfv(ucht1), Recombinant anti-cdr-bi-single-chain-fv-diphtheria toxin fusion protein, Recombinant anti-cdr-bi-single-chain-fv-diptheria toxin fusion protein, Resimmune |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Recombinant Anti-cdr-bi-single-chain-fv-diphtheria Toxin Fusion Protein
